



HAL
open science

Distinct pharmacological properties of morphine metabolites at G-protein and β -arrestin signaling pathways activated by the human μ -opioid receptor

Nadine Frölich, Christian Dees, Christian Paetz, Xuan Ren, Martin J. Lohse, Viacheslav O. Nikolaev, Meinhart H. Zenk

► To cite this version:

Nadine Frölich, Christian Dees, Christian Paetz, Xuan Ren, Martin J. Lohse, et al.. Distinct pharmacological properties of morphine metabolites at G-protein and β -arrestin signaling pathways activated by the human μ -opioid receptor. *Biochemical Pharmacology*, 2011, 10.1016/j.bcp.2011.03.001 . hal-00690183

HAL Id: hal-00690183

<https://hal.science/hal-00690183>

Submitted on 22 Apr 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Distinct pharmacological properties of morphine metabolites at G_i -protein and β -arrestin signaling pathways activated by the human μ -opioid receptor

Authors: Nadine Frölich, Christian Dees, Christian Paetz, Xuan Ren, Martin J. Lohse, Viacheslav O. Nikolaev, Meinhart H. Zenk



PII: S0006-2952(11)00145-6
DOI: doi:10.1016/j.bcp.2011.03.001
Reference: BCP 10840

To appear in: *BCP*

Received date: 17-1-2011
Revised date: 27-2-2011
Accepted date: 2-3-2011

Please cite this article as: Frölich N, Dees C, Paetz C, Ren X, Lohse MJ, Nikolaev VO, Zenk MH, Distinct pharmacological properties of morphine metabolites at G_i -protein and β -arrestin signaling pathways activated by the human μ -opioid receptor, *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2011.03.001

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Distinct pharmacological properties of morphine metabolites at G_i-protein
and β-arrestin signaling pathways activated by
the human μ-opioid receptor

Nadine Frölich¹, Christian Dees¹, Christian Paetz³, Xuan Ren⁴, Martin J. Lohse^{1,2},
Viacheslav O. Nikolaev^{1,2,*}, Meinhart H. Zenk⁴

¹Institute of Pharmacology, University of Würzburg, Versbacher Str. 9, D-97078, Germany

²Rudolf Virchow Center, DFG-Research Center for Experimental Biomedicine, University of
Würzburg, Versbacher Str. 9, D-97078, Germany

³Max-Planck-Institute for Chemical Ecology, Hans-Knöll-Str. 8, D-07745 Jena, Germany

⁴Donald Danforth Plant Science Center, 975 North Warson Road, St. Louis, MO 63132, USA

*Present address, also for correspondence:

Viacheslav O. Nikolaev, Ph.D.
Emmy-Noether Group of the DFG,
Department of Cardiology and Pneumology,
Georg-August University Medical Center,
Robert-Koch-Str. 40,
D-37075 Göttingen, Germany
Phone: +49-551-39-10965; Fax: +49-551-39-6389
E-mail: viacheslav.nikolaev@med.uni-goettingen.de

Biochemical Pharmacology. Category: Pharmacokinetics and Drug Metabolism

Abstract

1
2
3
4
5 Morphine and several other opioids are important drugs for the treatment of acute
6
7 and chronic pain. Opioid-induced analgesia is predominantly mediated by the μ -
8
9 opioid receptor (MOR). When administered to humans, complex metabolic pathways
10
11 lead to generation of many metabolites, nine of which may be considered major
12
13 metabolites. While the properties of the two main compounds, morphine-6-
14
15 glucuronide and morphine-3-glucuronide, are well described, the activity of other
16
17 morphine metabolites is largely unknown. Here we performed an extensive
18
19 pharmacological characterization by comparing efficacies and potencies of morphine
20
21 and its nine major metabolites for the two main signaling pathways engaged by the
22
23 human MOR, which occur via G_i -protein activation and β -arrestins, respectively. We
24
25 used radioligand binding studies and FRET-based methods to monitor MOR-
26
27 mediated G_i -protein activation and β -arrestin recruitment in single intact 293T cells.
28
29 This approach identified two major groups of morphine metabolites, which we
30
31 classified into “strong” and “weak” receptor ligands. Strong partial agonists morphine,
32
33 morphine-6-glucuronide, normorphine, morphine-6-sulfate, 6-acetylmorphine and 3-
34
35 acetylmorphine showed efficacies in the nanomolar range, while the weak
36
37 metabolites morphine-N-oxide, morphine-3-sulfate, morphine-3-glucuronide and
38
39 pseudomorphine activated MOR pathways only in the micromolar range.
40
41 Interestingly, three metabolites, normorphine, 6-acetylmorphine and morphine-6-
42
43 glucuronide, had lower potencies for G_i -protein activation but higher potencies and
44
45 efficacies for β -arrestin recruitment than morphine itself, suggesting that they are
46
47 biased towards β -arrestin pathways.
48
49
50
51
52
53
54
55
56
57
58

59 *Key words:* morphine, metabolite, FRET, G-protein, β -arrestin
60
61
62
63
64
65

1. Introduction

1
2
3
4 Morphine is an important alkaloid from opium poppy and serves as the prototypical
5 analgesic drug. Morphine and some other opioids, for example 3,6-di-acetylmorphine
6
7 (heroin) are also relevant for drug abuse. Analgesic effects of opioids are achieved
8
9 largely via activation of μ -opioid receptors (MOR) [1, 2]. MOR is a G-protein-coupled
10
11 receptor (GPCR), which can activate several cellular signaling pathways. The first
12
13 pathway is mediated by the activation of inhibitory pertussis-toxin sensitive G-
14
15 proteins ($G_{i/o}$ -proteins). The second pathway is induced by the recruitment of β -
16
17 arrestins to the receptor, which leads to subsequent activation of other, so-called
18
19 "non-classical" signaling cascades such as the mitogen activated protein kinase
20
21 pathway [3, 4].
22
23
24
25
26
27
28
29
30

31
32 When administered to humans, morphine and other opiate alkaloids undergo
33
34 extensive biotransformation by various metabolic pathways. The predominant
35
36 metabolic pathway involves conjugation with glucuronic acid, which leads to the
37
38 major metabolites morphine-3-glucuronide and morphine-6-glucuronide [5]. Other
39
40 metabolic pathways include conjugation with sulfonic acid, leading to morphine-6-
41
42 sulfates and morphine-3-sulfates, acetylation to 3- and 6-acetylmorphines, oxidation
43
44 to morphine-N-oxide and demethylation to normorphine [6, 7] (Fig. 1). Among all
45
46 known morphine metabolites, the pharmacological properties have been best studied
47
48 for morphine-6-glucuronide and morphine-3-glucuronide, which are generally
49
50 considered as active and inactive metabolites, respectively [8]. Much less is known
51
52 about the activity of other metabolites, since no systematic pharmacological analysis
53
54 has so far been performed, and only rare single reports on these compounds are
55
56
57
58
59
60
61
62
63
64
65

1 available. Lack of information about opiate metabolites does not allow definitive
2 conclusions about their roles in analgesia and in adverse effects of morphine [6, 7].
3
4
5

6
7 To study the pharmacological properties of various ligands for G protein-coupled
8 receptors, including MOR, we have developed a new real-time approach to monitor
9 G_i -protein activation in intact cells by using biosensors which are based on Förster
10 resonance energy transfer (FRET) [9, 10, 11]. In addition, we have developed
11 another technique to monitor β -arrestin recruitment to various receptors by
12 measuring FRET between a receptor and β -arrestin [12, 13]. These approaches
13 allow us to study pharmacological properties of different receptors and their ligands
14 in single intact cells with high temporal and spatial resolution [14, 15].
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 Here we used these FRET assays together with radioligand binding studies to
30 perform a systematic analysis of the pharmacological properties of all major
31 morphine metabolites at the human MOR. We found that morphine metabolites exert
32 either strong or weak signaling effects, often comparable to morphine itself, and that
33 some metabolites show a previously unrecognized β -arrestin-biased behavior and
34 are more efficacious in recruiting β -arrestin to the receptor than morphine itself.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2. Material and methods

2.1 Substances

Morphine, morphine-6-glucuronide, morphine-3-glucuronide and DAMGO ([D-Ala², N-MePhe⁴, Gly-ol]-enkephalin) were purchased from Sigma-Aldrich (Deisenhofen, Germany). Normorphine, 3-acetylmorphine and 6-acetylmorphine were from Lipomed GmbH (Weil am Rhein, Germany).

Morphine-N-oxide, morphine-3-sulfate, morphine-6-sulfate and pseudomorphine were synthesized as follows. Morphine-N-oxide and pseudomorphine were prepared as described by Garrido et al. [16]. Morphine-3-sulfate was prepared via 6-acetylmorphine as previously described [17] and further sulfonated and deprotected by a procedure described by Mori et al. [18]. Morphine-6-sulfate was synthesized from morphine hydrochloride according to Preechagoon et al. [19]. Except where noted, all other chemicals were obtained from Sigma-Aldrich.

2.2. Plasmids

Human MOR-1A cDNA was obtained from imaGenes GmbH (Berlin, Germany) and subcloned into the pcDNA3 expression vector (Invitrogen) using HindIII and XbaI restriction sites. All fluorescent G_i-protein subunits used to monitor G_i activation by FRET have previously been described [9, 10]. Briefly, the rat PTX-insensitive G_{ai1}-protein (C351I mutant) was labeled with enhanced yellow fluorescent protein (YFP) between positions 91 and 92. Human G_{γ2} was C-terminally tagged with enhanced cyan fluorescent protein (CFP), and the untagged human G_{β1} cDNA was co-

1 expressed. For the FRET-based measurements of β -arrestin-2 recruitment, the
2 plasmids encoding the human MOR-1A C-terminally tagged with CFP, bovine β -
3 arrestin-2 C-terminally tagged with YFP, and untagged human G protein-coupled
4 receptor kinase (GRK) 2 were used [12].
5
6
7
8
9

10 11 12 13 14 **2.3 Cell culture and transfections**

15
16
17 293T cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM)
18 supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 units/ml penicillin
19 and 0.1 mg/ml streptomycin (all from Pan Biotech GmbH, Aidenbach, Germany) at
20
21
22 37°C and 7% CO₂. Cells were seeded onto poly-D-lysine (Sigma) coated glass cover
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

To monitor G_i-protein activation, the following plasmids were transfected (μ g DNA per 6-well plate): MOR 0.7, G_{ai1}-YFP 0.8, G _{β 1} 0.5, G _{γ 2}-CFP 0.2. To measure β -arrestin recruitment, cells were transfected with (μ g DNA per 6-well plate): MOR-CFP 0.3, GRK2 0.2, β -arrestin-2-YFP 0.2). For receptor binding studies, 1.9 μ g MOR plasmid were transfected per 90 mm cell-culture dish.

51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

MOR expressing 293T cells were homogenized in 5 mM Tris, 2 mM EDTA, pH 7.4. The cell homogenate was centrifuged for 10 min at 1700xg, and the remaining

1 supernatant was centrifuged for 30 min at 50,000xg. The resulting pellet was
2 resuspended in 50 mM of potassium phosphate buffer, pH 7.4, and aliquots were
3
4 frozen in liquid nitrogen. 20 μ g of membrane protein were mixed with 0.1-1 nM of
5
6 3 [H]naloxone (American Radiolabeled Chemicals, Inc., St. Louis, USA), 100 μ M GTP
7
8 and various MOR ligand concentrations in 200 μ l of 50 mM potassium phosphate
9
10 buffer. Samples were incubated at room temperature for 3 h, then filtered through
11
12 GF/F glass fiber filters (Millipore, Schwalbach, Germany) before liquid scintillation
13
14 counting.
15
16
17
18
19
20
21
22

23 **2.5 FRET measurements**

24
25
26 FRET experiments were performed on a Zeiss Axiovert 200 inverted microscope with
27
28 a PLAN-Neofluar oil immersion 100x objective and a dual emission photometric
29
30 system as previously described [10]. Experiments were done at room temperature in
31
32 a buffer containing 144 mM NaCl, 5.4 mM KCl, 2 mM CaCl_2 , 1 mM MgCl_2 , 10 mM
33
34 HEPES, pH 7.3. Cells were excited using the monochromatic light from a
35
36 Polychrome IV (Till Photonics, Gräfelfing, Germany) at 436 nm \pm 10 nm and a
37
38 frequency of 5 Hz. Emitted light was separated by the DCLP 505 beam splitter into
39
40 two emission channels recorded at 480 \pm 20 nm (CFP) and 535 \pm 10 nm (FRET
41
42 channel). The F_{535}/F_{480} emission ratio was offline corrected for bleedthrough, direct
43
44 YFP excitation and photobleaching using Origin software in order to obtain corrected
45
46 $F_{\text{YFP/CFP}}$ ratios, which were used throughout the manuscript. Ratiometric traces were
47
48
49
50
51 normalized to the initial ratio (set to 1).
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3. Results

1
2 We analyzed the pharmacological properties of morphine and its nine major
3
4 metabolites in three types of assays, namely radioligand binding studies, G-protein
5
6 activation measurements and an assay to monitor β -arrestin recruitment to the opiate
7
8 receptor. These experiments were designed to compare the action of morphine
9
10 metabolites and their efficacies and potencies for two distinct signaling pathways
11
12 engaged by human MOR.
13
14
15

3.1 Radioligand binding studies

16
17
18
19
20
21
22 Initially, we determined the affinities of morphine and its major metabolites (plus
23
24 DAMGO as a reference agonist) for MOR in radioligand binding studies with cell
25
26 membranes prepared from 293T cells expressing the receptor, using the antagonist
27
28 [3 H]naloxone as the radioligand. Competition displacement curves for morphine and
29
30 DAMGO (Fig. 2) showed K_i -values, which were comparable to published values for
31
32 these ligands at the human MOR [20, 21]. Next, we measured the K_i -values of the
33
34 major morphine metabolites (see Fig. 1). The radioligand displacement curves (Fig.
35
36 2) revealed two groups of metabolites, which we classified into "strong" and "weak"
37
38 ligands. The "strong" metabolites, normorphine, 3- and 6-acetylmorphine, morphine-
39
40 6-glucuronide and -6-sulfate showed affinities in the nanomolar range, while the
41
42 "weak" ligands, pseudomorphine, morphine-N-oxide, morphine-3-glucuronide and -3-
43
44 sulfate, had micromolar K_i -values (Fig. 2 and Table 1).
45
46
47
48
49
50

3.2 G_i -protein activation

51
52
53
54
55
56 Based on these affinity measurements we then set out to investigate the metabolites'
57
58 functional effects. To monitor ligand-induced activation of inhibitory G-proteins, cells
59
60

1 expressing human MOR and fluorescently labeled G_i-protein subunits were treated
2 with the different morphine metabolites (Fig. 3A). In this assay, receptor activation
3 leads to a rapid and reversible decrease of the FRET ratio, which reflects structural
4 rearrangements between the G-protein subunits, and [9]. In MOR expressing cells,
5 we observed robust decreases of the FRET ratio upon morphine treatment, which
6 were even further enhanced by the full receptor agonist DAMGO, suggesting that
7 morphine acts only as a strong partial agonist at MOR (Fig. 3B). Addition of naloxone
8 on top of these ligands led to a complete, relatively slow, deactivation of G-proteins,
9 confirming that our system can be used to monitor specific pharmacological effects of
10 receptor agonists, partial agonists and antagonists (Fig. 3B).

11 Next, we set out to compare FRET responses produced by morphine with those
12 observed upon receptor activation with its various metabolites. Some of the
13 metabolites, for example morphine-6-glucuronide, showed a strong G-protein
14 activation signal, which had a similar amplitude as the response to morphine itself
15 (Fig. 3C). Other metabolites, for example morphine-N-oxide, even at high
16 concentrations, produced only partial effects, ranging from 70 to 90% of the morphine
17 response (Fig. 3D).

18 To systematically analyze efficacies and potencies of all major morphine metabolites,
19 we recorded concentration-response dependencies for the nine different compounds
20 and compared them to morphine by normalizing their maximal FRET responses to
21 the change of ratio evoked by the saturating morphine concentration of 10 μM. Again,
22 these experiments identified the two groups of morphine metabolites that were seen
23 in the radioligand binding experiments, i.e. the “strong” and “weak” ligands (Fig. 3E).
24 The strong metabolites all showed not only potencies in the nanomolar range, but
25 also efficacies at the MOR, which were comparable to morphine itself. These strong

1 partial MOR agonists were morphine-6-glucuronide, normorphine, morphine-6-sulfate
2 and both 3- and 6-acetylmorphine. The second group of "weak" metabolites had
3
4 much lower potencies and slightly lower efficacies compared to morphine. These
5
6 metabolites, morphine-N-oxide, morphine-3-sulfate and 3-glucuronide, as well as
7
8 pseudomorphine, were able to activate G_i -proteins only in the micromolar
9
10 concentration range, and their maximal effects ranged from 75 to 100% of those of
11
12 morphine (Fig. 3E, Table 1).
13
14
15
16
17
18

19 *3.3 β -Arrestin recruitment*

20
21 To monitor the activity of the second important group of signaling pathways activated
22
23 by MOR, we studied the effects of morphine metabolites on the ligand-induced β -
24
25 arrestin translocation to this receptor. We chose the previously well established
26
27 FRET-based approach which relies on the use of C-terminally CFP-tagged MOR and
28
29 C-terminally YFP-tagged β -arrestin-2 [12], which were transfected into 293T cells
30
31 together with the receptor kinase GRK2 to assure full agonist-triggered MOR
32
33 phosphorylation. Ligand-dependent MOR activation leads to GRK-mediated receptor
34
35 phosphorylation. Ligand-dependent MOR activation leads to GRK-mediated receptor
36
37 phosphorylation and subsequent β -arrestin-YFP recruitment, which can be monitored
38
39 as an increase of FRET (Fig. 4A). Again, morphine showed the typical response of a
40
41 partial agonist, which was ~30% smaller than the change of FRET ratio evoked by
42
43 the full MOR agonist DAMGO (Fig. 4B). Compatible with the need of prior GRK-
44
45 mediated receptor phosphorylation [12], these responses were slower than those
46
47 observed for G_i (compare Figs. 3B and 4B; note the different time scales). Next, we
48
49 continued to compare the FRET responses produced by morphine metabolites with
50
51 their parent compound. Strikingly, we found that some of the "strong" metabolites,
52
53 such as normorphine (Fig. 4C), morphine-6-glucuronide and 6-acetylmorphine,
54
55
56
57
58
59
60
61
62
63
64
65

1 induced a significantly stronger β -arrestin recruitment than morphine itself. Therefore,
2 we normalized all metabolite responses to the maximal FRET response produced by
3
4 10 μ M of DAMGO and measured concentration-response dependencies for all nine
5
6 morphine metabolites (Figs. 4D, E). As in the case of G_i -protein activation
7
8 experiments, there were again the two groups of "strong" and "weak" partial agonists,
9
10 which included the same members. Morphine-N-oxide and morphine-3-glucuronide
11
12 showed lower potencies and significantly lower efficacies compared to DAMGO and
13
14 morphine (Fig. 4D), while the other two weak metabolites were capable of
15
16 translocating β -arrestin to the same extent as morphine, but at much higher
17
18 concentrations (Fig. 4E and Table 1). Overall, the spread of efficacies was much
19
20 greater in this assay than in the G_i -activation assay (compare Figs. 3E and 4E).
21
22 Finally, we normalized the efficacies for all ligands measured in G_i - and β -arrestin
23
24 assays to the maximal DAMGO response to graphically compare the extent of
25
26 activation for each ligand and signaling pathway (Fig. 5)
27
28
29
30
31
32
33
34
35
36
37
38

39 4. Discussion

40
41
42
43
44 In this study, we performed a systematic analysis of the pharmacological properties
45
46 of morphine metabolites at the human MOR. We analyzed the ability of these
47
48 substances to bind to the receptor and to activate the two major independent
49
50 downstream signaling pathways, which are activation of G_i -proteins and β -arrestin
51
52 recruitment. The information obtained in these assays allows to predict, which of
53
54 these metabolites might play a role in MOR signaling *in vivo*.
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

To analyze MOR activation, we used novel FRET-based approaches for real-time monitoring of G_i-protein activation and β-arrestin recruitment. These approaches provide pharmacological information at the single-cell level and directly at the initiating biochemical event. While the results of FRET measurements of G_i-protein activation generally match well with the data obtained in classical GTPγS binding studies [10], they provide fast kinetic readouts and can be done in intact cells, i.e. under much more physiological conditions. Likewise, measurements of β-arrestin recruitment by FRET allow visualization of receptor/β-arrestin interaction in real time. These novel assays thus reflect the pharmacodynamic properties of receptor ligands at their target intact cells, but without the pharmacokinetic constraints typical for *in vivo* experiments. For example, morphine-6-glucuronide, when directly injected into mice, has been shown to induce its behavioral effects much slower than morphine [22]. However, in our study, we observed similarly fast kinetics of G_i-protein activation as well as comparable efficacies and potencies for the two substances. The discrepancy between the results of the single-cell experiments and *in vivo* studies can be explained by differences in pharmacokinetics, which largely depend on the chemical structure and parameters such as hydrophobicity of the various metabolites. Indeed, it has been demonstrated that both morphine glucuronides are much slower at crossing the blood-brain barrier than morphine [23]. The single-cell pharmacological analyses presented in this study are capable of directly reporting dynamic properties of signaling at the level of target cells and therefore reflect the real pharmacodynamics of these compounds at their receptor.

There are two sources of morphine and its metabolites which are relevant for the human body. One is exogenous morphine and other analgesic opiates, which are

1 administered for pain therapy or during opiate abuse. In this case, the circulating
2 opiate concentrations can reach relatively high micromolar peak levels, which
3 gradually decrease through metabolic pathways [22, 24]. The second source of
4 opiates in the human body is the endogenous morphine biosynthesis, which is
5 capable of producing high nanomolar concentrations of morphine from endogenous
6 biosynthetic precursors [25, 26, 27]. Much is known about the metabolic pathways
7 which lead to morphine conjugation and biotransformation (see Fig. 1). 60-70% of
8 exogenously administered morphine is conjugated [5] to morphine-3-glucuronide
9 (~55%) and morphine-6-glucuronide (~10%). After oral or parenteral morphine
10 administration to patients, slightly higher plasma concentrations of morphine-6-
11 glucuronide and ~10-times higher concentration of morphine-3-glucuronide can be
12 measured for up to 12 hours [24]. Morphine-3-glucuronide is a very weak metabolite,
13 whereas morphine-6-glucuronide can activate MOR almost as strongly as morphine.
14 For morphine-3- and morphine-6-glucuronides we were able to confirm the previously
15 observed differences [8] in their pharmacological properties. The former metabolite
16 has been classified as a weak MOR ligand, while the latter glucuronide is a strong
17 activator of MOR-induced signaling with potencies comparable to morphine.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 Much less has been known about the pharmacological properties of other
45 metabolites of morphine, which include normorphine, morphine-3- and morphine-6-
46 sulfates, as well as 3- and 6-acetylmorphines. Normorphine is the N-demethylated
47 metabolite of morphine which has been described as an active but slightly weaker
48 opioid receptor ligand compared to morphine or morphine-6-glucuronide [28, 29]. In
49 our study, we confirmed this observation and showed that normorphine activates G_i-
50 proteins at slightly higher concentrations than morphine. Morphine-6-sulfate, similarly
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

to morphine-6-glucuronide, is a potent ligand, which requires ~10-50-times lower parenteral dose to achieve an analgesic effect comparable to morphine [30]. In contrast, morphine-3-sulfate is a weaker metabolite, which has been described to have much lower binding affinity and lower analgesic potency [31, 32]. In this study, we found that morphine-6-sulfate has binding and signaling properties similar to morphine, so that the analgesic potency of this metabolite cannot be explained by distinct pharmacodynamic properties but must be pharmacokinetic in origin. Morphine-3-sulfate, however, was much less potent and fell into the group of weak metabolites, which is compatible with earlier observations. The 3- and 6-acetylmorphines, which represent important heroin metabolites, have been reported to have similar or slightly less potent pharmacological effects than morphine [31] which was also the case in our single-cell experiments. Likewise, the weak analgesic morphine-N-oxide, which has been found to be 10-90 times less potent than morphine [33], showed almost 1000 times lower affinity and potencies in FRET assays.

Interestingly, we found that three metabolites, normorphine, 6-acetylmorphine and morphine-6-glucuronide, showed lower potencies for G_i-protein activation but higher potencies and efficacies for β -arrestin recruitment than morphine (compare Fig. 2E and Fig. 3E, see also Table 1 and Fig. 5). This finding suggests that such ligands might have a bias for β -arrestin over G-protein signaling. Although they induce weaker responses at G-proteins, these metabolites can activate β -arrestin signaling pathways much stronger – pathways, which have been mostly associated with the pharmacological effects of opioid peptides.

1
2 Based on the results of this study, one can predict whether various opioid ligands,
3 especially morphine metabolites, can have pharmacological effects *in vivo*. In
4 physiological settings, weak metabolites would not activate MOR, because they do
5 not reach high micromolar concentrations, unless high opioid amounts have been
6 exogenously administered. Several strong metabolites, such as normorphine and
7 the main heroin metabolites 3- and 6-acetylmorphine, are much more relevant for
8 receptor activation. Endogenously synthesized morphine and its strong metabolites
9 might be pharmacologically relevant only if they are present at high nanomolar
10 concentrations. In addition, normorphine and 6-acetylmorphine, together with
11 morphine-6-glucuronide, can trigger previously unrecognized stronger activation of
12 the β -arrestin signalling.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 The most interesting aspect of this study is the observation that morphine
32 metabolites show differential preference for the two major signalling pathways
33 triggered by G_i-proteins and β -arrestins, respectively. A more detailed understanding
34 of these two signalling pathways in eliciting the various pharmacological effects of
35 morphine is certainly necessary before we might be able to exploit these differences
36 for drug therapy. However, our data clearly show that there is such a potential for
37 differential effects of morphine metabolites at the MOR.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgements

The study was supported by the Deutsche Forschungsgemeinschaft (SFB487), the European Research Council (TOPAS) and the National Institutes of Health (NIH) (5R21DA024418-02).

Abbreviations: DAMGO, [D-Ala², N-MePhe⁴, Gly-ol]-enkephalin; FRET, fluorescence (or: Förster) resonance energy transfer; GPCR, G-protein-coupled receptor; GRK, G-protein-coupled-receptor kinase.

References

- [1] Corbett AD, Henderson G, McKnight AT, Paterson SJ. 75 years of opioid research: the exciting but vain quest for the Holy Grail. *Br J Pharmacol* 2006; 147 Suppl 1: S153-62.
- [2] Jordan B, Devi LA. Molecular mechanisms of opioid receptor signal transduction. *Br J Anaesth* 1998; 81: 12-9.
- [3] Dang VC, Napier IA, Christie MJ. Two distinct mechanisms mediate acute mu-opioid receptor desensitization in native neurons. *J Neurosci* 2009; 29: 3322-7.
- [4] Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. *Science* 2005; 308: 512-7.
- [5] Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. *Clin Pharmacokinet* 1993; 24: 344-54.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [6] Smith HS. Opioid metabolism. *Mayo Clin Proc* 2009; 84: 613-24.
- [7] Skarke C, Lötsch J. Morphine metabolites: clinical implications. *Seminars in Anesthesia, Perioperative Medicine and Pain* 2002; 21: 258-64.
- [8] Wittwer E, Kern SE. Role of morphine's metabolites in analgesia: concepts and controversies. *AAPS J* 2006; 8: E348-52.
- [9] Bünemann M, Frank M, Lohse MJ. Gi protein activation in intact cells involves subunit rearrangement rather than dissociation. *Proc Natl Acad Sci U S A* 2003; 100: 16077-82.
- [10] Nikolaev VO, Boettcher C, Dees C, Bünemann M, Lohse MJ, Zenk MH. Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. *J Biol Chem* 2007; 282: 27126-32.
- [11] Lohse MJ, Nikolaev VO, Hein P, Hoffmann C, Vilardaga JP, Bünemann M. Optical techniques to analyze real-time activation and signaling of G-protein-coupled receptors. *Trends Pharmacol Sci* 2008; 29: 159-65.
- [12] Krasel C, Bünemann M, Lorenz K, Lohse MJ. Beta-arrestin binding to the beta2-adrenergic receptor requires both receptor phosphorylation and receptor activation. *J Biol Chem* 2005; 280: 9528-35.
- [13] Klenk C, Vetter T, Zürn A, Vilardaga JP, Friedman PA, Wang B, et al. Formation of a ternary complex among NHERF1, beta-arrestin, and parathyroid hormone receptor. *J Biol Chem* 2010; 285: 30355-62.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [14] Lohse MJ, Hein P, Hoffmann C, Nikolaev VO, Vilardaga JP, Bünemann M. Kinetics of G-protein-coupled receptor signals in intact cells. *Br J Pharmacol* 2008; 153 Suppl 1: S125-32.
- [15] Lohse MJ, Hoffmann C, Nikolaev VO, Vilardaga JP, Bünemann M. Kinetic analysis of G protein-coupled receptor signaling using fluorescence resonance energy transfer in living cells. *Adv Protein Chem* 2007; 74: 167-88.
- [16] Garrido JMPJ, Delerue-Matos C, Borges F, Macedo TRA, Oliveira-Brett AM. Voltammetric oxidation of drugs of abuse - I. Morphine and metabolites. *Electroanal* 2004; 16: 1419-26.
- [17] Wright CI. The enzymatic acetylation of heroin and related morphine derivatives by blood serum. *J Pharmacol Exp Ther* 1941; 71: 164-77.
- [18] Mori M, Oguri K, Yoshimura H, Shimomura K, Kamata O. Chemical synthesis and analgesic effect of morphine ethereal sulfates. *Life Sci* 1972; 11: 525-33.
- [19] Preechagoon D, Brereton I, Staatz C, Prankerd R. Ester prodrugs of a potent analgesic, morphine-6-sulfate: syntheses, spectroscopic and physicochemical properties. *Int J Pharm* 1998; 163: 177-90.
- [20] Befort K, Filliol D, Decaillet FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. *J Biol Chem* 2001; 276: 3130-7.
- [21] Spivak CE, Beglan CL, Seidleck BK, Hirshbein LD, Blaschak CJ, Uhl GR, et al. Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity. *Mol Pharmacol* 1997; 52: 983-92.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [22] Handal M, Grung M, Skurtveit S, Ripel A, Morland J. Pharmacokinetic differences of morphine and morphine-glucuronides are reflected in locomotor activity. *Pharmacol Biochem Behav* 2002; 73: 883-92.
- [23] Bickel U, Schumacher OP, Kang YS, Voigt K. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. *J Pharmacol Exp Ther* 1996; 278: 107-13.
- [24] Sawe J, Kager L, Svensson Eng JO, Rane A. Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation. *Br J Clin Pharmacol* 1985; 19: 495-501.
- [25] Boettcher C, Fellermeier M, Drager B, Zenk MH. How human neuroblastoma cells make morphine. *Proc Natl Acad Sci U S A* 2005; 102: 8495-500.
- [26] Poeaknapo C, Schmidt J, Brandsch M, Drager B, Zenk MH. Endogenous formation of morphine in human cells. *Proc Natl Acad Sci U S A* 2004; 101: 14091-6.
- [27] Zhu W, Cadet P, Baggerman G, Mantione KJ, Stefano GB. Human white blood cells synthesize morphine: CYP2D6 modulation. *J Immunol* 2005; 175: 7357-62.
- [28] Sullivan AF, McQuay HJ, Bailey D, Dickenson AH. The spinal antinociceptive actions of morphine metabolites morphine-6-glucuronide and normorphine in the rat. *Brain Res* 1989; 482: 219-24.
- [29] Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. *Ther Drug Monit* 1991; 13: 1-23.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [30] Zuckerman A, Bolan E, de Paulis T, Schmidt D, Spector S, Pasternak GW. Pharmacological characterization of morphine-6-sulfate and codeine-6-sulfate. *Brain Res* 1999; 842: 1-5.
- [31] Brown CE, Roerig SC, Burger VT, Cody RB, Jr., Fujimoto JM. Analgesic potencies of morphine 3- and 6-sulfates after intracerebroventricular administration in mice: relationship to structural characteristics defined by mass spectrometry and nuclear magnetic resonance. *J Pharm Sci* 1985; 74: 821-4.
- [32] Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. *Life Sci* 1991; 48: 2165-71.
- [33] Fennessy MR. The analgesic action of morphine-n-oxide. *Br J Pharmacol* 1968; 34: 337-44.

Figure legends

1
2
3
4
5 **Figure 1.** Metabolic pathways by which morphine undergoes biotransformation in the
6 human body. The majority of the alkaloid is conjugated with glucuronic acid to form
7 morphine-3- and -6-glucuronides. The remainder can be modified to form other
8 metabolites such as sulfate or acetyl esters, normorphine, morphine-N-oxide and
9 pseudomorphine (adapted from [7]).
10
11
12
13
14
15
16
17
18
19

20 **Figure 2.** Competition radioligand displacement curves for [³H]-naloxone measured
21 with 293T cell membranes expressing human MOR and treated with various ligands.
22 Data are presented as means ± SE (n=4-8). Individual data points were fitted to a
23 single binding site model, and the obtained K_i -values are presented in the Table 1.
24
25
26
27
28
29
30

31 **Figure 3.** Real-time monitoring of the morphine metabolite-induced effects on MOR-
32 mediated G_{i1} -protein activation. (A) The FRET system for real-time monitoring of G_{i1} -
33 protein activation in cells expressing MOR and fluorescently labeled G-protein
34 subunits. FRET between CFP fused to the γ_2 -subunit of the $\beta\gamma$ -complex, and YFP on
35 the α_{i1} -subunit shows high basal levels, which decrease upon receptor-mediated
36 activation. (B) Effects of saturating morphine (10 μ M) and DAMGO (10 μ M)
37 concentrations on the FRET signal (presented as the normalized YFP/CFP ratio).
38 Morphine acts as a partial agonist at the receptor and G_i -protein when compared to
39 DAMGO. The MOR antagonist naloxone can fully block this FRET response. (C)
40 Morphine-6-glucuronide (10 μ M) produces a rapid FRET signal, which is comparable
41 in its magnitude to that of morphine. (D) A weak metabolite morphine-N-oxide, even
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 at high concentrations (300 μM), shows only a partial FRET signal. B-D are
2 representative experiments (n=3-7). (E) Concentration-response dependencies for
3 morphine and its nine major metabolites measured in the FRET assay reflecting
4 MOR-mediated G_i -protein activation. Changes in FRET are normalized to the
5 maximal response induced by 10 μM morphine. Data are presented as means \pm SE
6 (n=3-7).
7
8
9
10
11
12
13
14
15
16

17 **Figure 4.** Measurements of β -arrestin recruitment to the activated MOR by FRET. (A)
18 The FRET system for real-time monitoring of receptor/ β -arrestin interaction is based
19 on using MOR, which is tagged with CFP on its C-terminus, and the YFP-tagged β -
20 arrestin-2. Recruitment of β -arrestin-2-YFP to the activated receptor results in an
21 increase of FRET. (B) Effects of the partial agonist morphine (10 μM), full agonist
22 DAMGO (10 μM) and MOR antagonist naloxone (10 μM) on the FRET signal. (C)
23 Normorphine (10 μM) induces a stronger β -arrestin recruitment compared to
24 morphine (10 μM). (D) The weak metabolite morphine-N-oxide (300 μM) shows a
25 partial effect on β -arrestin recruitment. B-D are representative experiments (n=4-7).
26
27 (E) Concentration-response dependencies for DAMGO, morphine and its nine major
28 metabolites for the MOR-mediated β -arrestin recruitment. Changes in FRET are
29 normalized to the maximal response induced by 10 μM DAMGO. Data are presented
30 as means \pm SE (n=4-7).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **Figure 5.** Correlation of efficacies which various opioid ligands have at activating
53 MOR-dependent G-protein and β -arrestin signaling. Data are taken from Figures 3E
54 and 4E and normalized to the maximal effects induced by 10 μM DAMGO. Several
55
56
57
58
59
60
61
62
63
64
65

1 ligands elicit comparable effects on both pathways (e.g. DAMGO, morphine,
2 morphine-N-oxide), while others more prominently activate β -arrestin signaling (e.g.
3
4 normorphine, 6-acetylmorphine, morphine-6-glucuronide).
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1. Pharmacological properties of various morphine metabolites at the human μ -opioid receptor (MOR) measured by radioligand binding and FRET assays. EC_{50} values for G_i -protein activation and β -arrestin recruitment in the FRET-based assays show concentrations at which a half-maximal response for each individual substance was observed. Data from competitive displacement experiments using $^3[H]$ -naloxone and MOR-expressing cell membranes are presented as K_i values. All data are means \pm SE calculated from three to seven independent experiments.

Substance	Assay		
	G_i activation EC_{50} (μ M), means \pm SE	β -arrestin recruitment EC_{50} (μ M), means \pm SE	Binding K_i (μ M), means \pm SE
DAMGO	0.046 \pm 0.004	0.060 \pm 0.002	0.005 \pm 0.002
Morphine	0.015 \pm 0.002	0.457 \pm 0.157	0.022 \pm 0.004
Morphine-6-glucuronide	0.037 \pm 0.008	0.338 \pm 0.062	0.063 \pm 0.014
Normorphine	0.040 \pm 0.007	0.267 \pm 0.015	0.061 \pm 0.013
3-Acetylmorphine	0.057 \pm 0.010	0.594 \pm 0.019	0.098 \pm 0.029
Morphine-6-sulfate	0.053 \pm 0.005	0.196 \pm 0.036	0.047 \pm 0.004
6-Acetylmorphine	0.100 \pm 0.021	0.339 \pm 0.023	0.054 \pm 0.022

Morphine-N-oxide	2.2 ± 0.4	16.7 ± 1.3	3.4 ± 1.0
Morphine-3-sulfate	3.2 ± 0.5	20.1 ± 6.8	4.7 ± 1.1
Morphine-3-glucuronide	8.2 ± 1.4	23.7 ± 4.8	6.1 ± 0.4
Pseudomorphine	9.5 ± 0.6	53.6 ± 4.3	3.6 ± 1.8

Accepted Manuscript

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

